Publications
2014
- Initial Dose of a Multicomponent Serogroup B Meningococcal Vaccine in the Saguenay–Lac-Saint-Jean Region, Québec, Canada: An Interim Safety Surveillance Report
- Rapport intérimaire de surveillance de la sécurité de la première dose du vaccin contre le méningocoque de sérogroupe B au Saguenay–Lac-St-Jean
Publications
2015
- Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
- Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.
- Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada
- Measles in Canada Between 2002 and 2013.
- Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.
- Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada
2014
- Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness
- Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season
- Human metapneumovirus viral load is an important risk factor for disease severity in young children
- Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses
2013
- Measles in children vaccinated with 2 doses of MMR
- The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials
- Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine
- Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events
- Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine